Abstract: OBJECTIVE To introduce kinds of cediranib's antitumor effects in clinic. METHODS According to the correlative reports in recent years, clinical trial of the seven areas of ovarian cancer, solid tumors, biliary tract cancer, renal cell carcinoma, prostate cancer, cervical cancer and colon cancer were reviewed. RESULTS Cediranib was a potent inhibitor of VEGFR, datas from clinical studies of cediranib suggested its potential anti-tumor effect. Pharmacokinetic studies showed that it was oral administration, once daily, conveniently, and it's toxicity was similar to other VEGFR inhibitors. CONCLUSION Familiar with the clinical application of cediranib, has profound significance for the development of better cediranib.